Landos Biopharma, Inc.
LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS
Last updated:
Abstract:
Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Status:
Application
Type:
Utility
Filling date:
20 Oct 2020
Issue date:
18 Feb 2021